Log in
Enquire now
‌

US Patent 11352348 Splicing modulator antibody-drug conjugates and methods of use

Patent 11352348 was granted and assigned to Eisai (company) on June, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Eisai
Eisai
Current Assignee
Eisai
Eisai
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11352348
Patent Inventor Names
Zhenhua Wu0
Thiwanka Samarakoon0
Xiang Liu0
Yonghong Xiao0
Andrew Cook0
Dominic Reynolds0
Ermira Pazolli0
James Palacino0
...
Date of Patent
June 7, 2022
Patent Application Number
17247117
Date Filed
November 30, 2020
Patent Primary Examiner
‌
Brian J Davis

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11352348 Splicing modulator antibody-drug conjugates and methods of use

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.